The approval for plaque PsO was based on data from the PROTOSTAR trial, which evaluated guselkumab in participants aged 6 to 17 years with moderate to severe plaque PsO.
Qivigy (immune globulin intravenous, human-kthm) is a ready-to-use, sterile, non-pyrogenic liquid solution of human immune globulin for IV administration.
The DESTINY-Breast05 trial included patients with HER2-positive primary breast cancer who were at high risk of recurrence and had residual invasive disease in breast or axillary lymph nodes following ...
HealthDay News — A 16-week Mediterranean diet intervention significantly improves psoriasis severity in patients with mild-to-moderate disease receiving stable topical therapy, according to a study ...
Private equity hospitals reduced ED and ICU salary expenditures after acquisition relative to control hospitals.
HealthDay News — Sprout Organics has widened its recall of 3.5-ounce Sweet Potato, Apple & Spinach pouches because some lots may contain elevated levels of lead. The Food and Drug Administration (FDA) ...
HealthDay News — Prevention strategies for cardiovascular manifestations of acute and long COVID are discussed in a report published online September 18 in the European Journal of Preventive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback